Harbert Fund Advisors Inc. Has $5.05 Million Position in InfuSystem Holdings, Inc. (NYSE:INFU)

Harbert Fund Advisors Inc. reduced its position in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 597,613 shares of the company’s stock after selling 20,472 shares during the quarter. InfuSystem comprises about 2.6% of Harbert Fund Advisors Inc.’s portfolio, making the stock its 6th biggest position. Harbert Fund Advisors Inc. owned approximately 2.81% of InfuSystem worth $5,050,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its holdings in shares of InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after purchasing an additional 1,626 shares in the last quarter. State Street Corp raised its holdings in InfuSystem by 1.1% during the third quarter. State Street Corp now owns 267,012 shares of the company’s stock worth $1,789,000 after buying an additional 3,019 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of InfuSystem by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,286 shares of the company’s stock valued at $78,000 after buying an additional 3,165 shares in the last quarter. Perritt Capital Management Inc grew its holdings in shares of InfuSystem by 14.3% during the fourth quarter. Perritt Capital Management Inc now owns 44,000 shares of the company’s stock valued at $372,000 after buying an additional 5,500 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of InfuSystem by 74.1% during the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock worth $104,000 after acquiring an additional 6,623 shares in the last quarter. Institutional investors own 71.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Sidoti upgraded InfuSystem to a “strong-buy” rating in a research note on Tuesday, March 18th. StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, March 14th.

InfuSystem Trading Down 3.2 %

Shares of INFU stock opened at $4.91 on Friday. InfuSystem Holdings, Inc. has a 12-month low of $4.61 and a 12-month high of $9.97. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $6.55 and a 200-day moving average of $7.42. The firm has a market cap of $103.19 million, a P/E ratio of 81.85 and a beta of 1.90.

InfuSystem Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.